Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|August 26, 2026

The BioPharm Brief: RAS, CAR-T, and Synthetic DNA

Listen
0:00 / 0:00

Today’s BioPharm Brief covers FDA approval of daraxonrasib for metastatic pancreatic cancer, the first patient dosed in HaemaLogiX’s KMCAR CAR-T trial, and a new collaboration to advance cell-free synthetic DNA for viral vector manufacturing.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Here’s what we have for today.

First, the FDA has approved daraxonrasib for previously treated metastatic pancreatic ductal adenocarcinoma, making it the first approved RAS(ON) inhibitor and the first therapy to validate a tri-complex approach to targeting active RAS. The once-daily oral drug, developed by Revolution Medicines, was supported by Phase 3 RASolute 302 data showing median overall survival of 13.2 months versus 6.7 months with chemotherapy. The approval came about six and a half months ahead of the FDA’s action date after the application received Breakthrough Therapy, Orphan Drug, Priority Review, and Commissioner’s National Priority Voucher designations.

In multiple myeloma, HaemaLogiX has dosed the first patient in its Phase 1 KOALA trial of KMCAR T-cell therapy. The autologous CAR-T is designed to target the Kappa Myeloma Antigen on kappa-restricted malignant plasma cells while sparing healthy immune cells. The approach differs from BCMA-directed CAR-T therapies by focusing on a more selective target. The first patient was reported to have tolerated the initial infusion without serious adverse events, and a second patient has entered the dose-escalation study.

And in manufacturing, 4basebio and Genezen are expanding a collaboration around cell-free synthetic DNA. The non-exclusive agreement will give developers access to 4basebio’s research-use, high-quality, and GMP-grade synthetic DNA for viral vector programs. The cell-free process eliminates bacterial backbone sequences and antibiotic resistance genes from the DNA starting material. In AAV production, the companies say the technology has produced comparable titers to plasmid DNA while using about 30% less DNA mass and transfection reagent.

That’s The BioPharm Brief for today. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Daraxonrasib becomes the first approved RAS(ON) inhibitor in metastatic pancreatic cancer.
  • HaemaLogiX moves its kappa-targeted CAR-T into first-in-human clinical testing.
  • 4basebio and Genezen are bringing cell-free synthetic DNA into viral vector manufacturing.

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more